GlaxoSmithKline concludes previously announced agreement in principle to resolve multiple investigations with US Government and numerous states

GlaxoSmithKline plc announced that it has reached an agreement with the US Government, multiple states and the District of Columbia to conclude the Company’s most significant ongoing Federal government investigations.

Read the full story >>

NovoPen® 5 wins the red dot Best of the Best design award
At an award ceremony in Essen, Germany, Novo Nordisk was awarded the red dot Best of the Best prize for its next-generation insulin injection pen, the NovoPen® 5...

GSK and Theravance announce positive results from four pivotal phase III studies for once-daily LAMA/LABA (UMEC/VI) in COPD
GlaxoSmithKline plc and Theravance, Inc. have announced the results of four pivotal phase III studies of investigational LAMA/LABA involving over 4,000 patients with COPD...

Bristol-Myers Squibb and AstraZeneca expand diabetes alliance through Bristol-Myers Squibb’s acquisition of Amylin Pharmaceuticals
Bristol-Myers Squibb Company and Amylin Pharmaceuticals, Inc. announced that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash...

Biogen Idec and Isis announce global collaboration for antisense program targeting myotonic dystrophy
Biogen Idec and Isis Pharmaceuticals, Inc. have entered into an exclusive, worldwide option and collaboration agreement under which the companies will develop and commercialize a novel antisense drug...

GSK sets 20 July for expiration of tender offer to acquire Human Genome Sciences
GlaxoSmithKline plc has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences...

Marketing and manufacturing approval received for TENELIA(R) 20mg tablets
Mitsubishi Tanabe has received approval to manufacture and market the selective DPP-4 inhibitor TENELIA® 20mg tablets in Japan...

Gilead submits New Drug Application to U.S. FDA for boosting agent cobicistat
Gilead Sciences, Inc. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat...

Two-year study in over 1,500 patients compares Trajenta® (linagliptin) to the commonly prescribed sulphonylurea glimepiride
Results from a two-year study published...

New Phase 3 data show STELARA® significantly reduced signs and symptoms of active Psoriatic Arthritis
Treatment also resulted in significant improvements in physical function...

Gilead submits NDA to U.S. FDA for HIV integrase inhibitor elvitegravir for treatment-experienced patients
Elvitegravir is also a component of Quad single tablet regimen...

AstraZeneca and Merck agree to amend second option
AstraZeneca and Merck have agreed to amend certain provisions of the agreements relating to the companies’ arrangements in the US...

Abbott, The Abbott Fund and Direct Relief International reach key HIV testing milestone
20 million tests provided over 10 years & more than 150,000 HIV cases prevented...

VELCADE® receives positive regulatory recommendation in the European Union for subcutaneous administration
New route of administration provides improved safety and greater convenience...

Bristol-Myers Squibb & Pfizer receive response from FDA for ELIQUIS® (apixaban)
Additional information requested from ARISTOTLE trial results...

Abbott receives positive opinion for HUMIRA® in non-radiographic axial spondyloarthritis from EMA’s CHMP
Abbott announced that the CHMP has issued a positive opinion for HUMIRA®...

GEA Pharma Systems interviewed at ACHEMA 2012
Frans K.A. Maas, Vice President Sales & Marketing, GEA Pharma Systems speaks to Freddy White, Director of the European Pharmaceutical Review at ACHEMA 2012.